Nuveen
MGX icon

Nuveen’s Metagenomi Therapeutics MGX Stock Holding History

Nuveen’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6K Buy
+4,052
New +$4.88K ﹤0.01% 4639
2025
Q2 		– Sell
-63,248
Closed -$86K – 3433
2025
Q1 		$86K Hold
63,248
– – ﹤0.01% 3228
2024
Q4 		$228K Buy
+63,248
New +$153K ﹤0.01% 3184

Other funds holding MGX

Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
FAG
Fortitude Advisory Group Gig Harbor, Washington $262M AUM 30.62% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nuveen's MGX Position: Q3 2026 in Review

Nuveen opened a new position in Metagenomi Therapeutics (MGX) in Q3 2026: 4,052 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #4639 among its holdings. This is a return to the name: Nuveen previously reported a position in MGX as recently as Q1 2025.

Nuveen first reported a position in MGX in Q4 2024 and has held it in 3 quarters since. The position peaked at $228K in Q4 2024. 10 funds tracked by Wall St. Rank hold MGX as of Q3 2026.

  • Nuveen held 4,052 shares of Metagenomi Therapeutics worth $6K as of Q3 2026.
  • Metagenomi Therapeutics was a new Nuveen position in Q3 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4639 holding.
  • Nuveen first reported a position in Metagenomi Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Nuveen's Metagenomi Therapeutics position peaked at $228K in Q4 2024.
  • 10 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.